Rybelsus Bioavailability and Pharmacokinetics, From the FDA Label
The FDA-approved Rybelsus prescribing information states an absolute bioavailability of approximately 0.4% to 1% for oral semaglutide — a figure so much lower than the injected form that the two cannot be compared milligram for milligram. This page records what the label says, names the section behind each figure, and explains why that number is the most important one on the page. Reference material, not clinical guidance.
· Educational content — not medically reviewed
The short answer
Rybelsus bioavailability is estimated in the FDA-approved prescribing information, Section 12.3 via DailyMed, at approximately 0.4% to 1% after oral administration — so little of an oral semaglutide dose is absorbed that tablet milligrams and injection milligrams describe different quantities of drug. The same section gives a half-life of approximately one week, peak concentration about one hour post dose, and steady state after four to five weeks. Reference material, not clinical guidance.
Key takeaways
- The Rybelsus prescribing information (Section 12.3, via FDA accessdata and DailyMed, accessed 1 September 2026) estimates absolute bioavailability at approximately 0.4% to 1% after oral administration of the 3 mg, 7 mg and 14 mg tablets.
- The same section states an elimination half-life of approximately one week — identical to injected semaglutide, because it is the same molecule.
- Maximum concentration is reached approximately 1 hour after oral administration, and steady-state exposure is achieved following 4 to 5 weeks of once-daily administration.
- Because so little of an oral dose is absorbed, tablet milligrams and injection milligrams describe completely different quantities of drug in the body. Comparing them directly is the single most common error made about this medication.
- Not clinician-reviewed and not medical advice. No dosing instruction of any kind appears on this page.
Absolute bioavailability: approximately 0.4% to 1%
Section 12.3 of the Rybelsus prescribing information estimates absolute bioavailability at approximately 0.4% to 1% after oral administration of the 3 mg, 7 mg and 14 mg tablets (accessed 1 September 2026). Well under one percent of a swallowed dose typically reaches the circulation.
Half-life: approximately one week
The same section gives an elimination half-life of approximately one week — the same figure the injection labels give, because the molecule is the same. What differs between the two routes is entirely absorption, not clearance.
Time to peak: approximately 1 hour
Maximum concentration is reached approximately 1 hour after oral administration. This is a genuinely different figure from the injection's 1-to-3-day window, and it is a consequence of the absorption route rather than of the molecule.
A range, not a single number
The label gives a range because absorption of oral semaglutide is variable. Any source quoting a single precise bioavailability percentage for Rybelsus has picked a point inside a labeled range rather than reported a labeled value.
What this page is, and what it is not
This is a reference page. Its job is to reproduce, accurately and with attribution, the pharmacokinetic statements in the FDA-approved United States prescribing information for Rybelsus, so somebody keeping a personal medication record can see where the numbers they encounter come from.
It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication is appropriate for anybody. It does not tell you how much to take, when to take it, or how to take it. Those belong to your prescriber, your pharmacist and the label that came with your own prescription.
That last point carries more weight for an oral product than for an injection, and the reason is explained in its own section below.
GLP-1 Tracker visualizes your estimated medication level over time.
The primary source behind every number here
All figures on this page come from one document: RYBELSUS (semaglutide) tablets, for oral use — the United States Prescribing Information approved by the FDA. The pharmacokinetic statements sit in Section 12.3, Pharmacokinetics.
The copy consulted was read via FDA accessdata and DailyMed, the National Library of Medicine's mirror of current FDA-approved labeling, accessed 1 September 2026. The label records an Initial U.S. Approval of 2017. Section 3 lists the tablet strengths as 3 mg, 7 mg and 14 mg.
One distinction is worth making early, because it is a live source of confusion. Rybelsus is not the only oral semaglutide product, and the other one carries a different labeled bioavailability range. Figures quoted for one should never be attributed to the other. Everything on this page is Rybelsus's own label.
Labels are revised, which is why the access date is printed beside the figures. If a number here ever conflicts with the current label, the current label wins.
The bioavailability figure, and why it dominates everything else
Section 12.3 estimates the absolute bioavailability of semaglutide at approximately 0.4% to 1% following oral administration of the 3 mg, 7 mg and 14 mg tablets.
Absolute bioavailability is the fraction of an administered dose reaching systemic circulation unchanged, measured against an intravenous reference. A figure below one percent is extraordinarily low, and it is the defining fact about this product. Peptides are poorly suited to oral delivery — they are broken down in the gut and cross the intestinal wall badly — and the low, variable absorption in the label is the direct consequence.
This is why a tablet strength and an injection strength are not comparable quantities. They are numbers on different scales. A reader who reasons from tablet milligrams to injection milligrams, in either direction, will be wrong by roughly two orders of magnitude, and the error is not subtle.
Why the label gives a range rather than a number
The label's phrasing is an estimate expressed as a range, and that phrasing is itself informative.
Absorption of oral semaglutide is variable — between people, and to some degree between occasions. A range is the honest way to describe a quantity that does not settle on a single value, and the fact that the approved labeling declines to give a point estimate is a signal about how much precision the underlying data supports.
This matters when you meet a single precise percentage quoted elsewhere, including inside reference tables and tracking software. Such a figure is a working value somebody selected from inside the labeled range in order to make a calculation possible. It is a modelling convenience, not a labeled fact, and it should be described that way.
Half-life and time to peak: same molecule, different journey
Section 12.3 states an elimination half-life of approximately one week, and that maximum concentration is reached approximately 1 hour after oral administration. Steady-state exposure is achieved following 4 to 5 weeks of once-daily administration.
The half-life figure is the same as for injected semaglutide, and that is exactly as it should be: half-life describes how quickly the body clears a molecule once it is in the circulation, and the molecule is identical. Route of administration changes how a drug gets in, not what happens to it afterwards.
Time to peak is where the routes genuinely diverge. Roughly an hour for the tablet against a one-to-three-day window for the injection. And note what the combination produces: a rapid rise from each dose sitting on top of a slowly clearing background, which is why a daily tablet still takes weeks to reach a steady level.
Why this page does not reproduce the administration instructions
The Rybelsus label conditions administration on specific circumstances — fasting state, the quantity of liquid taken with the tablet, and a waiting period before other intake — and those conditions materially affect how much drug is absorbed.
This page states that such conditions exist and that they matter, because that is a genuine pharmacological fact and it explains the bioavailability figure above. It does not reproduce them as steps, and it will not. They are administration instructions, and a reader who follows a website's version of them instead of the label that came with their own prescription has been badly served.
If you take this medication, the instructions that apply to you are the ones on your own prescription and from your pharmacist. If you are unsure whether you are taking it correctly, that is a question worth asking them directly. It is one of the more consequential questions in this drug class, precisely because absorption is so sensitive.
What a tracking app can legitimately record
GLP-1 Tracker treats an oral medication as a record-keeping problem in the same way it treats an injection, with one practical difference: the cadence is daily rather than weekly, so what is worth recording is adherence over time rather than individual events.
What it records is what you enter: which days you logged a dose, weight and BMI entries over time, meals captured through the photo scan with calories, protein and fiber estimated, and notes about how a stretch of days went. It holds them in one timeline rather than scattered across a notes app and memory.
What it does not do is decide anything. It does not evaluate whether your routine is working, it does not flag anything as clinically significant, and it does not generate schedules. Its value is in producing an accurate history when somebody qualified asks what has actually been happening.
The medication-level estimate, and where it breaks down
GLP-1 Tracker includes an educational medication-level view that draws a curve from logged doses and a published half-life figure. For an oral product the curve also has to account for how little of each dose is absorbed, and that correction is drawn from a labeled range rather than measured.
So the curve for a tablet is a modelled illustration resting on a second modelled assumption. It is a teaching aid, useful for seeing why a daily tablet accumulates over weeks rather than days, and it is nothing more than that. It cannot account for your own absorption, which is the very quantity the label declines to state precisely.
It is not a measurement, not a blood level, and not a clinical reading. Treating it as information about your own body, or letting it influence anything you do, would be a misuse of it.
Frequently asked questions
What is the bioavailability of Rybelsus?
The FDA-approved Rybelsus prescribing information estimates absolute bioavailability at approximately 0.4% to 1% following oral administration of the 3 mg, 7 mg and 14 mg tablets (Section 12.3, accessed 1 September 2026). It is stated as a range rather than a single figure because absorption of oral semaglutide is variable, and any single precise percentage quoted elsewhere is a value chosen from inside that range.
Why is Rybelsus bioavailability so low?
Semaglutide is a peptide, and peptides are poorly suited to oral delivery: they are degraded in the gastrointestinal tract and cross the intestinal wall inefficiently. The label's estimate of roughly 0.4% to 1% is the direct consequence. This is a description of what the label reports, not an explanation of anything about your own treatment.
Is Rybelsus's half-life different from the injection's?
No. Section 12.3 states an elimination half-life of approximately one week, the same figure the semaglutide injection labels give. Half-life describes how quickly the body clears a molecule once it has reached the circulation, and the molecule is identical. What differs between tablet and injection is absorption, not clearance.
How long does Rybelsus take to reach peak concentration?
The label states that maximum concentration was reached approximately 1 hour after oral administration (Section 12.3, accessed 1 September 2026). That is a genuinely different figure from the injection's 1-to-3-day window, and it reflects the route of administration rather than any difference in the molecule.
Can I compare Rybelsus milligrams to Ozempic milligrams?
No, and it is the most common error made about this medication. Because well under one percent of an oral dose typically reaches the circulation against 89% for the injection, tablet milligrams and injection milligrams describe quantities on completely different scales. Any direct comparison will be wrong by roughly two orders of magnitude.
Has this page been reviewed by a doctor?
No. This is a reference page assembled from publicly available FDA-approved labeling, with the document, section and access date printed beside each figure so you can verify any of it. It has not been written or reviewed by a clinician, it is not medical advice, and it is not a substitute for professional care.
A daily tablet is an adherence record, not an event log
GLP-1 Tracker keeps the days you logged, your weight trend and your meals in one timeline, so the history you bring to an appointment is accurate rather than remembered. Educational and organizational only — never a substitute for your provider.
Reading on a desktop? Scan to open it on your iPhone.apps.apple.com/app/id6765520636
This page is for general education only and is not medical advice, diagnosis or treatment. GLP-1 Tracker is a tracking tool, not a medical device. Always consult your healthcare provider about your medication, dosing and health decisions. Brand names are trademarks of their respective owners and are not affiliated with this app.